These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 23725277)

  • 1. Counteracting immunosuppressive cofactor B7-H1 may enhance the effects of chemotherapy in cancer patients.
    Liu Q; Gong W; Cheng Z; Jiang H; Cao F; Li X
    Immunotherapy; 2013 Jun; 5(6):557-9. PubMed ID: 23725277
    [No Abstract]   [Full Text] [Related]  

  • 2. The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone.
    Afreen S; Dermime S
    Hematol Oncol Stem Cell Ther; 2014 Mar; 7(1):1-17. PubMed ID: 24398144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of adjuvant chemotherapy and immunotherapy in gastric cancer.
    Labianca R; Panvini D
    Pathol Biol (Paris); 1993 Jan; 41(1):80-1. PubMed ID: 8316482
    [No Abstract]   [Full Text] [Related]  

  • 4. Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas.
    Chen J; Li G; Meng H; Fan Y; Song Y; Wang S; Zhu F; Guo C; Zhang L; Shi Y
    Cancer Immunol Immunother; 2012 Jan; 61(1):101-8. PubMed ID: 21853301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adjuvant treatment of cancers of the stomach].
    Bedenne L
    Gastroenterol Clin Biol; 1994; 18(8-9):733-6. PubMed ID: 7875442
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic targeting of B7-H1 in breast cancer.
    Hasan A; Ghebeh H; Lehe C; Ahmad R; Dermime S
    Expert Opin Ther Targets; 2011 Oct; 15(10):1211-25. PubMed ID: 21870995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combined chemoimmunotherapy in stomach cancer and hematosarcoma].
    Britsis FA; Zakenfel'd GK; Krampe RA; Berzinia VIu; Purkalne TS
    Vopr Onkol; 1980; 26(5):72-7. PubMed ID: 6770541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could PD-L1 prove to be an effective therapeutic target for bladder cancer?
    Hafez N; Petrylak DP
    Immunotherapy; 2015; 7(1):1-2. PubMed ID: 25572474
    [No Abstract]   [Full Text] [Related]  

  • 10. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
    Thompson RH; Gillett MD; Cheville JC; Lohse CM; Dong H; Webster WS; Krejci KG; Lobo JR; Sengupta S; Chen L; Zincke H; Blute ML; Strome SE; Leibovich BC; Kwon ED
    Proc Natl Acad Sci U S A; 2004 Dec; 101(49):17174-9. PubMed ID: 15569934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The intraperitoneal administration of chemical preparations and taktivin in the combined treatment of stomach cancer].
    Shchepotin IB; Chernyĭ VA; Grinevich IuA; Kamenets LIa; Osinskiĭ SP
    Vrach Delo; 1988 Sep; (9):3-6. PubMed ID: 3212989
    [No Abstract]   [Full Text] [Related]  

  • 12. CTLA-4 blockade: autoimmunity as treatment.
    Kapadia D; Fong L
    J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
    [No Abstract]   [Full Text] [Related]  

  • 13. Dendritic cell therapy in advanced gastric cancer: a promising new hope?
    Tewari M; Sahai S; Mishra RR; Shukla SK; Shukla HS
    Surg Oncol; 2012 Sep; 21(3):164-71. PubMed ID: 22521560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma.
    Thompson RH; Webster WS; Cheville JC; Lohse CM; Dong H; Leibovich BC; Kuntz SM; Sengupta S; Kwon ED; Blute ML
    Urology; 2005 Nov; 66(5 Suppl):10-4. PubMed ID: 16194701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy.
    Ophir R; Pecht M; Keisari Y; Rashid G; Lourie S; Meshorer A; Ben-Efraim S; Trainin N; Burstein Y
    Immunopharmacol Immunotoxicol; 1996 May; 18(2):209-36. PubMed ID: 8771368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?
    Dos Santos Fernandes G; da Motta Girardi D; Dib Batista Bugiato Faria L; Giacomini Bernardes JP; de Almeida Coudry R
    J Immunother Cancer; 2017 Nov; 5(1):84. PubMed ID: 29157298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
    Hamid O; Carvajal RD
    Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H1 and B7-DC receptors of oral squamous carcinoma cells are upregulated by Porphyromonas gingivalis.
    Groeger S; Domann E; Gonzales JR; Chakraborty T; Meyle J
    Immunobiology; 2011 Dec; 216(12):1302-10. PubMed ID: 21723642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Modifiers of the biological response in the adjuvant treatment of digestive cancers].
    Seitz JF
    Gastroenterol Clin Biol; 1994; 18(8-9):726-32. PubMed ID: 7875441
    [No Abstract]   [Full Text] [Related]  

  • 20. Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy.
    Wu Y; Wang L; Zhang Y
    Cell Mol Immunol; 2004 Oct; 1(5):351-6. PubMed ID: 16285894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.